This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Schwander B, Lindgren P, Gradl B.The cost-effectiveness (cost-utility) of eprosartan in hypertensive patients with cerebrovascular disease in Belgium, Germany, Spain, United Kingdom, and Sweden. Value in Health 10: A237-A238 (plus oral presentation) abstr. CV8, No. 6, Nov-Dec 2007
Rights and permissions
About this article
Cite this article
Eprosartan worth it in hypertension + cerebrovascular disease. Pharmacoecon. Outcomes News 541, 8 (2007). https://doi.org/10.2165/00151234-200705410-00011
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200705410-00011